Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) Director George Morrow sold 7,500 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $145.79, for a total transaction of $1,093,425.00. Following the completion of the sale, the director owned 10,386 shares of the company’s stock, valued at $1,514,174.94. The trade was a 41.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Neurocrine Biosciences Trading Up 0.7%
NASDAQ NBIX opened at $166.05 on Thursday. The company has a fifty day simple moving average of $146.98 and a 200 day simple moving average of $147.77. The company has a market cap of $16.81 billion, a P/E ratio of 24.64, a P/E/G ratio of 0.73 and a beta of 0.36. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $186.12.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. Neurocrine Biosciences’s revenue was up 41.3% compared to the same quarter last year. During the same period last year, the business posted $2.04 EPS. Equities research analysts forecast that Neurocrine Biosciences, Inc. will post 7.66 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on NBIX. BMO Capital Markets lowered their price target on Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating on the stock in a research report on Monday, October 12th. Piper Sandler lifted their price objective on Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Tuesday. UBS Group cut their price objective on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Needham & Company LLC restated a “buy” rating and set a $204.00 target price on shares of Neurocrine Biosciences in a research note on Friday, October 16th. Finally, Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $202.32.
Check Out Our Latest Report on Neurocrine Biosciences
Neurocrine Biosciences News Roundup
Here are the key news stories impacting Neurocrine Biosciences this week:
- Positive Sentiment: Neurocrine reported Q3 revenue of $1.12 billion, up 41% year over year and above expectations, with EPS of $3.29 also beating estimates. The company raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion, reflecting product demand and supporting the growth outlook. Q3 results and updated sales outlook
- Positive Sentiment: Guggenheim raised its price target to $224 from $207 and maintained a Buy rating. Canaccord, Piper Sandler and RBC also lifted their targets after the results, adding to a broadly favorable analyst response.
- Neutral Sentiment: The company has started a Phase 2 Alzheimer’s study, offering a potential longer-term pipeline opportunity, but the supplied report provides few details on the study or its prospects. Alzheimer’s study update
- Negative Sentiment: Director George J. Morrow reported selling shares in multiple transactions, including sales on November 2 and 3. The filings indicate the trades were made under a pre-arranged Rule 10b5-1 plan, which may lessen the significance, but insider selling can still concern investors.
- Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, which could affect how much value the company ultimately captures from the deal. Soleno acquisition risks
Hedge Funds Weigh In On Neurocrine Biosciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. Parallel Advisors LLC grew its position in Neurocrine Biosciences by 3.5% in the 3rd quarter. Parallel Advisors LLC now owns 1,780 shares of the company’s stock worth $252,000 after purchasing an additional 61 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 0.5% during the 1st quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock worth $1,721,000 after purchasing an additional 68 shares during the period. Entrust Financial LLC increased its holdings in shares of Neurocrine Biosciences by 62.9% during the 3rd quarter. Entrust Financial LLC now owns 202 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the period. Keybank National Association OH increased its holdings in shares of Neurocrine Biosciences by 4.7% during the 3rd quarter. Keybank National Association OH now owns 2,001 shares of the company’s stock worth $284,000 after purchasing an additional 89 shares during the period. Finally, Westpac Banking Corp raised its position in shares of Neurocrine Biosciences by 6.0% during the first quarter. Westpac Banking Corp now owns 1,615 shares of the company’s stock valued at $213,000 after buying an additional 91 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.
Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.
Read More
- Five stocks we like better than Neurocrine Biosciences
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
